Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1551380

Cover Image

PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1551380

Global In Vivo Toxicology Market Size study, by Product, by Test Type, by Testing Facility, by Toxicity End Point, by End User, and Regional Forecasts 2022-2032

PUBLISHED:
PAGES: 285 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4950
Printable PDF (Enterprise License)
USD 6250

Add to Cart

Global In Vivo Toxicology Market was valued at USD 5.49 billion in 2023 and is projected to grow with a healthy growth rate of more than 5.6% over the forecast period 2024-2032. In vivo toxicology, a critical branch of toxicology, involves studying the toxic effects of substances on live animal models. This field is pivotal for understanding the absorption, distribution, metabolism, and excretion (ADME) of various substances, providing indispensable insights into their potential toxicological impacts. Such studies are instrumental in ensuring the safety and efficacy of new pharmaceuticals, chemicals, and other products before they reach the market.

The market for in vivo toxicology is driven by several compelling factors. Firstly, the relentless advancement in drug development within the pharmaceutical industry necessitates comprehensive in vivo toxicology studies. These studies are indispensable for ascertaining the safety and efficacy of new compounds before they proceed to clinical trials. The burgeoning prevalence of chronic diseases and the incessant need for novel treatments propel the pharmaceutical sector's investment in research and development, thereby augmenting the demand for in vivo toxicology testing. Additionally, stringent regulatory frameworks that mandate exhaustive safety assessments of drugs and chemicals further drive the market. Regulatory bodies, including the FDA and EMA, require extensive toxicological evaluations to ensure new products' safety, compelling companies to conduct in vivo toxicology studies to meet compliance standards. Technological advancements have significantly enhanced the precision and efficiency of in vivo toxicology studies. Innovations in imaging technologies, biomarkers, and data analysis tools allow researchers to obtain more accurate and detailed insights into substances' effects on living organisms. These advancements reduce the time and cost associated with toxicology testing, encouraging broader adoption and market growth. Furthermore, the expanding biotechnology sector and the rising focus on personalized medicine create substantial growth opportunities for the market. However, ethical and animal welfare concerns associated with animal testing pose significant challenges. Increasing scrutiny from animal rights organizations and the public has led to calls for alternative testing methods, potentially impacting the demand for traditional in vivo toxicology studies.

North America, particularly the US and Canada, dominated the market in 2023, accounting for the highest market share. This dominance is attributed to the region's high demand for personalized medicines and the expansion of the stem cell research sector in Canada, driven by large-scale investments and the implementation of the Canadian Stem Cell Strategy and Action Plan. The presence of well-established players and favourable government reimbursement policies further bolster the market in North America. The Asia Pacific region is expected to exhibit the fastest growth rate over the forecast period, driven by growing investments in healthcare infrastructure and increasing adoption of advanced testing methodologies.

Major market players included in this report are:

  • Charles River Laboratories (US)
  • The Jackson Laboratory (US)
  • Envigo (US)
  • Taconic Biosciences, Inc. (US)
  • JANVIER LABS (France)
  • Thermo Fisher Scientific (US)
  • Danaher Corporation (US)
  • Waters Corporation (US)
  • Agilent Technologies (US)
  • Shimadzu Corporation (Japan)
  • Bruker Corporation (US)
  • PerkinElmer (US)
  • Merck KGaA (Germany)
  • GE Healthcare (US)
  • Bio-Rad Laboratories (US)

The detailed segments and sub-segment of the market are explained below:

By Product:

  • Instruments
  • Consumables

By Test Type:

  • Acute
  • Sub-acute
  • Sub-chronic
  • Chronic test type

By Testing Facility:

  • Outsourced testing facility
  • In-house testing facility

By Toxicity End Point:

  • Immunotoxicity
  • Systemic toxicity
  • Carcinogenicity
  • Genotoxicity
  • Developmental & reproductive toxicity (DART)
  • Other toxicity endpoints

By End User:

  • Academic and Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Other End Users

By Region:

North America:

  • U.S.
  • Canada

Europe:

  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE

Asia Pacific:

  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC

Latin America:

  • Brazil
  • Mexico
  • RoLA

Middle East & Africa:

  • Saudi Arabia
  • South Africa
  • RoMEA

Years considered for the study are as follows:

  • Historical year - 2022
  • Base year - 2023
  • Forecast period - 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global In Vivo Toxicology Market Executive Summary

  • 1.1. Global In Vivo Toxicology Market Size & Forecast (2022- 2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Product
    • 1.3.2. By Test Type
    • 1.3.3. By Testing Facility
    • 1.3.4. By Toxicity End Point
    • 1.3.5. By End User
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global In Vivo Toxicology Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global In Vivo Toxicology Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Advancements in Drug Development
    • 3.1.2. Regulatory Requirements
    • 3.1.3. Technological Advancements
  • 3.2. Market Challenges
    • 3.2.1. Ethical and Animal Welfare Concerns
  • 3.3. Market Opportunities
    • 3.3.1. Growing Biotechnology Sector
    • 3.3.2. Rising Focus on Personalized Medicine

Chapter 4. Global In Vivo Toxicology Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
    • 4.1.7. Porter's 5 Force Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top investment opportunity
  • 4.4. Top winning strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global In Vivo Toxicology Market Size & Forecasts by Product 2022-2032

  • 5.1. Segment Dashboard
  • 5.2. Global In Vivo Toxicology Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 5.2.1. Instruments
    • 5.2.2. Consumables

Chapter 6. Global In Vivo Toxicology Market Size & Forecasts by Test Type 2022-2032

  • 6.1. Segment Dashboard
  • 6.2. Global In Vivo Toxicology Market: Test Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 6.2.1. Acute
    • 6.2.2. Sub-acute
    • 6.2.3. Sub-chronic
    • 6.2.4. Chronic test type

Chapter 7. Global In Vivo Toxicology Market Size & Forecasts by Testing Facility 2022-2032

  • 7.1. Segment Dashboard
  • 7.2. Global In Vivo Toxicology Market: Testing Facility Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 7.2.1. Outsourced testing facility
    • 7.2.2. In-house testing facility

Chapter 8. Global In Vivo Toxicology Market Size & Forecasts by Toxicity End Point 2022-2032

  • 8.1. Segment Dashboard
  • 8.2. Global In Vivo Toxicology Market: Toxicity End Point Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 8.2.1. Immunotoxicity
    • 8.2.2. Systemic toxicity
    • 8.2.3. Carcinogenicity
    • 8.2.4. Genotoxicity
    • 8.2.5. Developmental & reproductive toxicity (DART)
    • 8.2.6. Other toxicity endpoints

Chapter 9. Global In Vivo Toxicology Market Size & Forecasts by End User 2022-2032

  • 9.1. Segment Dashboard
  • 9.2. Global In Vivo Toxicology Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 9.2.1. Academic and Research Institutes
    • 9.2.2. Pharmaceutical & Biotechnology Companies
    • 9.2.3. Contract Research Organizations
    • 9.2.4. Other End Users

Chapter 10. Global In Vivo Toxicology Market Size & Forecasts by Region 2022-2032

  • 10.1. North America In Vivo Toxicology Market
    • 10.1.1. U.S. In Vivo Toxicology Market
      • 10.1.1.1. Product breakdown size & forecasts, 2022-2032
      • 10.1.1.2. Test Type breakdown size & forecasts, 2022-2032
      • 10.1.1.3. Testing Facility breakdown size & forecasts, 2022-2032
      • 10.1.1.4. Toxicity End Point breakdown size & forecasts, 2022-2032
      • 10.1.1.5. End User breakdown size & forecasts, 2022-2032
    • 10.1.2. Canada In Vivo Toxicology Market
  • 10.2. Europe In Vivo Toxicology Market
    • 10.2.1. U.K. In Vivo Toxicology Market
    • 10.2.2. Germany In Vivo Toxicology Market
    • 10.2.3. France In Vivo Toxicology Market
    • 10.2.4. Spain In Vivo Toxicology Market
    • 10.2.5. Italy In Vivo Toxicology Market
    • 10.2.6. Rest of Europe In Vivo Toxicology Market
  • 10.3. Asia-Pacific In Vivo Toxicology Market
    • 10.3.1. China In Vivo Toxicology Market
    • 10.3.2. India In Vivo Toxicology Market
    • 10.3.3. Japan In Vivo Toxicology Market
    • 10.3.4. Australia In Vivo Toxicology Market
    • 10.3.5. South Korea In Vivo Toxicology Market
    • 10.3.6. Rest of Asia Pacific In Vivo Toxicology Market
  • 10.4. Latin America In Vivo Toxicology Market
    • 10.4.1. Brazil In Vivo Toxicology Market
    • 10.4.2. Mexico In Vivo Toxicology Market
    • 10.4.3. Rest of Latin America In Vivo Toxicology Market
  • 10.5. Middle East & Africa In Vivo Toxicology Market
    • 10.5.1. Saudi Arabia In Vivo Toxicology Market
    • 10.5.2. South Africa In Vivo Toxicology Market
    • 10.5.3. Rest of Middle East & Africa In Vivo Toxicology Market

Chapter 11. Competitive Intelligence

  • 11.1. Key Company SWOT Analysis
  • 11.2. Top Market Strategies
  • 11.3. Company Profiles
    • 11.3.1. Charles River Laboratories
      • 11.3.1.1. Key Information
      • 11.3.1.2. Overview
      • 11.3.1.3. Financial (Subject to Data Availability)
      • 11.3.1.4. Product Summary
      • 11.3.1.5. Market Strategies
    • 11.3.2. The Jackson Laboratory
    • 11.3.3. Envigo
    • 11.3.4. Taconic Biosciences, Inc.
    • 11.3.5. JANVIER LABS
    • 11.3.6. Thermo Fisher Scientific
    • 11.3.7. Danaher Corporation
    • 11.3.8. Waters Corporation
    • 11.3.9. Agilent Technologies
    • 11.3.10. Shimadzu Corporation
    • 11.3.11. Bruker Corporation
    • 11.3.12. PerkinElmer
    • 11.3.13. Merck KGaA
    • 11.3.14. GE Healthcare
    • 11.3.15. Bio-Rad Laboratories

Chapter 12. Research Process

  • 12.1. Research Process
    • 12.1.1. Data Mining
    • 12.1.2. Analysis
    • 12.1.3. Market Estimation
    • 12.1.4. Validation
    • 12.1.5. Publishing
  • 12.2. Research Attributes
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!